Publications and Posters - Affimed

All categories

Publications

Posters

All Cell Engagers

acimtamig (AFM13)

AFM11

AFM24

AFM26

AFM28

Innate Cell Engager

All years

2025

2024

2023

2022

2021

2020

2019

2018

2017

2016

2015

2014

2013

2012

2011

2010

2009

AFM26: A first-in-class, high affinity bispecific NK-cell engager targeting BCMA to treat multiple myeloma

Gantke et al.
EACR-AACR-SIC 2017 Special Conference

High affinity bispecific EGFR/CD16A antibodies specifically recruit NK-cells to target EGFR-expressing tumors

Kluge et al.
EACR-AACR-SIC 2017 Special Conference

AFM26 is a novel, highly potent BCMA/CD16A-directed bispecific antibody for high affinity NK-cell engagement in multiple myeloma

Gantke et al.
ASCO 2017 AFM26

Highly Specific and Effective Targeting of EGFRvIII-Positive Tumors with TandAb Antibodies

Ellwanger et al.
Front Oncol. 2017 May 19; 7:100. doi: 10.3389/fonc.2017.00100. eCollection 2017.

link to publication

EGFR/CD16A TandAbs are efficacious NK-cell engagers with favorable biological properties which potently kill EGFR+ tumors with and without Ras mutation

Kluge et al.
AACR 2017 – AFM24

Identification of antibodies against a novel tumor-associated MHC/peptide-target and generation of highly specific and potent HLA-A*02MMP1-003/CD3 TandAbs

Weinschenk et al.
AACR 2017 – MHC

AFM26 - A novel CD16A-directed bispecific TandAb targeting BCMA for multiple myeloma

Gantke et al.
AACR 2017 – AFM26

Characterization of CD33/CD3 Tetravalent Bispecific Tandem Diabodies (TandAbs) for the Treatment of Acute Myeloid Leukemia

Reusch et al.
Clin Cancer Res. 2016 Dec 1; 22(23):5829-5838. Epub 2016 May 17.

link to publication

T- or NK-cell recruiting anti-EGFRvIII TandAbs are highly specific and potent therapeutic antibody candidates for the treatment of EGFRvIII+ tumors

Ellwanger et al.
AACR 2016

Highly cytotoxic EGFR/CD16A TandAbs specifically recruit NKcells to potently kill various types of solid tumors

Ellwanger et al.
AACR 2016

1
2
3
4
5
6
7
8